Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells
Phase 1Recruiting 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Spinal Cord Injury
Conditions
Spinal Cord Injury, Safety, Clinical Trials, Efficacy, Induced Pluripotent Stem Cells, Human Motor Neuron Progenitor, Transplantation
Trial Timeline
Jul 2, 2025 → May 30, 2028
NCT ID
NCT06976229About Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells is a phase 1 stage product being developed by Sun Pharmaceutical for Spinal Cord Injury. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06976229. Target conditions include Spinal Cord Injury, Safety, Clinical Trials.
What happened to similar drugs?
7 of 20 similar drugs in Spinal Cord Injury were approved
Approved (7) Terminated (1) Active (12)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06974968 | Phase 2 | Recruiting |
| NCT06976229 | Phase 1 | Recruiting |
Competing Products
20 competing products in Spinal Cord Injury
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUN13837 injection + Placebo | Daiichi Sankyo | Phase 2 | 35 |
| Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mg | Astellas Pharma | Phase 2 | 35 |
| Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells | Sun Pharmaceutical | Phase 2 | 42 |
| Elezanumab | AbbVie | Pre-clinical | 30 |
| Elezanumab + Placebo | AbbVie | Phase 2 | 35 |
| Ropivacaine + Bupivacaine | AstraZeneca | Phase 3 | 40 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 1 | 21 |
| Zolgensma | Novartis | Pre-clinical | 33 |
| BVS857 + Placebo | Novartis | Phase 2 | 35 |
| AVXS-101 | Novartis | Phase 1 | 29 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 44 |
| Onasemnogene Abeparvovec-brve | Novartis | Approved | 50 |
| Onasemnogene Abeparvovec-xioi | Novartis | Pre-clinical | 30 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 40 |
| branaplam | Novartis | Phase 1/2 | 32 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 40 |
| onasemnogene abeparvovec | Novartis | Phase 3 | 47 |
| onasemnogene abeparvovec-xioi | Novartis | Phase 3 | 40 |
| Risdiplam | Roche | Phase 1 | 29 |
| ATI355 | Novartis | Phase 1 | 29 |